Motexafin gadolinium

Motexafin gadolinium

Clinical data
ATC code	none
Identifiers
CAS Number	156436-89-4
PubChem (CID)	158385
ChemSpider	139341
KEGG	D05080
ChEBI	CHEBI:50161
Chemical and physical data
Formula	C52H72GdN5O14
Molar mass	1148.403 g/mol
3D model (Jmol)	Interactive image
SMILES [Gd+3].[O-]C(=O)C.[O-]C(=O)C.n1c3\C(=C(/c1cnc5cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc5ncc/4nc(cc2[n-]c(c(c2CC)CC)c3)\C(=C\4C)CCCO)C)CCCO
InChI InChI=1S/C48H66N5O10.2C2H4O2.Gd/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40;2*1-2(3)4;/h27-32,54-55H,7-26H2,1-6H3;2*1H3,(H,3,4);/q-1;;;+3/p-2/b39-27-,40-28-,41-27-,42-28-,45-31-,46-32-,49-31+,49-43+,50-32+,50-44+;;; Key:VAZLWPAHMORDGR-WRIGXHCHSA-L
(verify)

Motexafin gadolinium (proposed tradename Xcytrin) is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible chemotherapeutic agent in the treatment of brain metastases.^[1]

History

On May 9, 2006, a New Drug Application was submitted to the United States Food and Drug Administration (FDA) by Pharmacyclics, Inc.^[2]

On December 2007, the FDA issued a not approvable letter for motexafin gadolinium.^[3]

References

1. Richards G, Mehta M (2007). "Motexafin gadolinium in the treatment of brain metastases". Expert opinion on pharmacotherapy. 8 (3): 351–9. doi:10.1517/14656566.8.3.351. PMID 17266469.
2. Pharmacyclics, Inc. press release - Pharmacyclics to Submit New Drug Application for Xcytrin for Treatment of Lung Cancer Patients With Brain Metastases
3. Pharmacyclics, Inc. press release - Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases